Drug intelligence / Profile preview

VT-A2

Development stage: Preclinical
Lead developer: VASTHERA
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules

Overview

VT-A2 is a preclinical small molecule drug candidate being developed by VASTHERA for the treatment of triple-negative breast cancer (TNBC). It is developed using VASTHERA's proprietary Redoxizyme™ platform, which focuses on creating small-molecule peroxiredoxin (Prx) nanozymes. These compounds are designed to mimic the catalytic activity of natural peroxiredoxin enzymes, which are essential for regulating reactive oxygen species (ROS) and maintaining cellular redox homeostasis. By acting as a Prx mimetic, VT-A2 aims to modulate the oxidative stress environment within the tumor microenvironment, potentially inhibiting the growth, survival, and chemoresistance of aggressive TNBC cells.

Targets

PRDX2 (Peroxiredoxin-2)

Beyond the preview

Go deeper on VT-A2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VT-A2.

Explore the full profile